[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-hemorrhage":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,83,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100652345","bedside-cranial-ultrasound-for-risk-stratified-imaging-in-pediatric-acute-brain-injury-100652345",false,"NCT07772323","Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury","Bedside Cranial Point-of-Care Ultrasound (cPOCUS) for Risk-Stratified Imaging in Pediatric Acute Brain Injury: A Prospective Diagnostic-Accuracy and Longitudinal Biomarker Cohort Study (CUPID-Peds)","CUPID-Peds","Inclusion Criteria:\n\n* Children 2 to 17 years of age\n* Undergoing a clinically indicated (standard-of-care) head CT for suspected acute brain injury (including trauma, headache with neurologic findings, altered mental status, focal deficit, seizure, post-cardiac-arrest, oncologic neurologic emergency, or intracranial infection)\n* Seen in the pediatric Emergency Department or Pediatric Intensive Care Unit at the Children's Hospital of Richmond at VCU (CHoR-VCU)\n* Consent obtainable from a legally authorized representative (LAR)\n* Cranial ultrasound feasible within the protocol time window (within 6 hours of head CT)\n\nExclusion Criteria:\n\n* Open skull fracture\n* Prior hemicraniectomy\n* Cranial surgical defect at the insonation site\n* Anticipated transition to comfort-only care\n* Any clinical condition in which cranial ultrasound would delay a time-critical intervention","ALL","2 Years","17 Years",{"count":21,"type":22},220,"ESTIMATED","OBSERVATIONAL","Acute brain injury (ABI) is a leading cause of death and long-term disability in children. Diagnosis depends on fast neuroimaging, and head computed tomography (CT) is the bedside reference standard despite exposing the developing brain to ionizing radiation. A safe, portable, radiation-free bedside tool is needed to help decide which children need a head CT, to speed CT when injury is present, and to safely monitor injured children between scans. This study evaluates B-mode cranial point-of-care ultrasound (cPOCUS) performed through the temporal (and frontal) bone windows in children undergoing a clinically indicated head CT in the pediatric emergency department (ED) and pediatric intensive care unit (PICU). Children's thin skulls provide adequate acoustic windows in more than 95% of cases. cPOCUS is acquired by trained research scanners within 6 hours of head CT and interpreted offline by two blinded expert readers; the radiology CT report is the diagnostic gold standard. This is a prospective observational study; cPOCUS results are not returned to the clinical team in real time and do not change clinical care.",[26,27,28,29,30,31,32],"Acute Brain Injury","Traumatic Brain Injury","Intracranial Hemorrhage","Hydrocephalus","Stroke","Brain Neoplasm","Hypoxia-Ischemia, Brain",[34,35,36,37,38,39,40,41,42,43],"cranial ultrasound","point-of-care ultrasound","cPOCUS","transcranial B-mode ultrasound","pediatric neuroimaging","head CT","midline shift","diagnostic accuracy","radiation reduction","neurocritical care","NOT_YET_RECRUITING","2026-08-13",{"date":47,"type":48},"2026-08-19","ACTUAL",{"date":50,"type":22},"2026-11-30",{"date":52,"type":22},"2028-11-30",{"name":54,"class":55},"Virginia Commonwealth University","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":56},"100645430","phase-2-clinical-study-to-evaluate-the-efficacy-of-febuxostat-in-the-treatment-of-conservatively-managed-intracranial-hemorrhage-patients-100645430","NCT07701512","Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients","Inclusion Criteria:\n\n* • Age ≥ 18 years old.\n\n  * Diagnosed with intracranial hemorrhage confirmed by CT scan.\n  * Managed conservatively regarding clinical guidelines.\n  * Able to provide informed consent or have a legal representative provide consent.\n\nExclusion Criteria:\n\n* • Patients with a history of previous brain surgery or significant neurological disorders.\n\n  * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).\n  * Allergy or contraindication to febuxostat.\n  * Pregnant or breastfeeding women.\n  * Patients requiring surgical intervention for hematoma evacuation.\n  * Renal impairment with SCr \\> 4\n  * Liver impairment with INR \\> 5\n  * Significant deterioration ( GCS \\\u003C 8 )","18 Years",{"count":65,"type":22},46,"INTERVENTIONAL",[68],"PHASE2","To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.",[28],[72],"Intracranial hemorrhage","RECRUITING","2026-07-14",{"date":76,"type":48},"2026-07-15",{"date":78,"type":48},"2025-11-20",{"date":80,"type":22},"2027-01-30",{"name":82,"class":55},"Tanta University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":23,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":56},"100565970","clearance-of-intracranial-blood-products-by-continuous-irrigation-with-the-irraflow-system-100565970","NCT06649097","Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System","CRYSTAL","Inclusion criteria:\n\n* Age \\>=18 years of age\n* Intracranial hemorrhage documented on head CT or MRI scan.\n* Indication for active fluid exchange evaluated by treating physician.\n* Signed informed consent obtained by patient or Legal Authorized Representative\n* Scheduled enrollment and treatment within 72 hours of last known well (LKW)\n\nExclusion criteria:\n\n* GCS ≤ 5\n* Pregnancy\n* Fixed and dilated pupil\n* Life-threatening medical condition",{"count":91,"type":22},250,"6 Months","The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.",[28,95,96],"Ventriculitis","Intracranial Abscess","2025-10-24",{"date":99,"type":48},"2025-10-28",{"date":101,"type":48},"2025-09-25",{"date":103,"type":22},"2031-07",{"name":105,"class":55},"Christopher P Kellner",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":66,"phases":117,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100599727","statins-for-treatment-of-primary-intracerebral-hemorrhage-100599727","NCT07088250","Statins for Treatment of Primary Intracerebral Hemorrhage","Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)","STOP ICH","Inclusion Criteria:\n\n* Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);\n* Age 18-80 years;\n* Hematoma located in the supratentorial region;\n* Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;\n* Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;\n* Glasgow Coma Scale (GCS) score ≥9;\n* Baseline hematoma volume of 5-35 mL;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;\n* Patients who have undergone or are scheduled for immediate surgical intervention;\n* Pregnancy or lactation;\n* Use of oral anticoagulants within 1 month prior to symptom onset;\n* Pre-stroke mRS \\>1;\n* Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;\n* Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.","80 Years",{"count":116,"type":22},264,[118],"NA","The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.",[121,122,28,123],"Cerebrovascular Disorders","Intracranial Hemorrhages","Intracerebral Haemorrhage",[125,126,127,128],"Intracerebral hemorrhage","Treatment","Atorvastatin","Outcome","2025-07-20",{"date":131,"type":48},"2025-07-28",{"date":133,"type":48},"2023-05-06",{"date":135,"type":22},"2026-12-31",{"name":137,"class":55},"The Second Hospital of Anhui Medical University",22]